Evidence map›Paper›PMID 38183109›Full record

ArticleVirology journal2024

Production of recombinant HPV11/16 E6/E7-MBP-His

Mei-Nian Xu, Mei-Zhen Zhong, Si-Ning Feng, Yan-Qin Xu, Xiao-Ming Peng, Kang Zeng, Xiao-Wen Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mei-Nian Xu *Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Mei-Zhen Zhong *Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Si-Ning FengDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yan-Qin XuDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiao-Ming PengDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Kang ZengDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. nfpfkzk@126.com.
Xiao-Wen HuangDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. huangxw@smu.edu.cn.
Nanfang Hospital · CN

Funding

National Natural Science Foundation of China 82103725Outstanding Youth Development Scheme of Nanfang Hospital, Southern Medical University 2018J003
6 · The paper itself

Abstract

Human papillomavirus (HPV) infection poses a significant threat to public health worldwide. Targeting the function of HPV E6 and E7 proteins and activating the host immune response against these proteins represent promising therapeutic strategies for combating HPV-related diseases. Consequently, the efficient production of soluble, high-purity E6 and E7 proteins is crucial for function and host immune response studies. In this context, we selected the pMCSG19 protein expression vector for Escherichia coli to produce soluble MBP-His

Indexed as

Leukocytes, MononuclearPapillomavirus InfectionsCytokinesEscherichia coliHumansRecombinant ProteinsCytokinesRecombinant ProteinsCytokineE6 proteinE7 proteinHuman papillomavirusMaltose binding proteinRecombinant protein

Identifiers

PMID38183109
PMCPMC10768090
OpenAlexW4390615954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.